A Phase 1 interventional study of CS-1103 and Sterile Saline in Substance Use Disorders, Methamphetamine Abuse and Methamphetamine Intoxication, sponsored by Clear Scientific, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-10.
Sponsored by Clear Scientific, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,589 studies in Substance-Related Disorders with a site in United States — 249 open to participants now, 313 under way, 4 of them phase 3. Substance-Related Disorders · United States.
Among the 1,589 studies in Substance-Related Disorders with a site in United States, this one is the 1,141st largest by enrollment of the 1,447 interventional ones that give a count, is one of 74 that started in 2024, is one of 131 in phase 1, and was the 1,362nd registered.
2,241 studies on the registry are indexed under Substance-Related Disorders; 409 are open to participants now.
Browse Substance-Related Disorders studies →249 of the 1,589 studies in Substance-Related Disorders with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 18+ · Healthy volunteers
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 18–120
National Institute on Drug Abuse (NIDA) · Sites in United States
Ages 18–65 · Healthy volunteers
University of Massachusetts, Worcester · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 264 Substance-Related Disorders studies recruiting now, 129 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 89 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,589 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 172 · Phase 2 242 · Phase 3 79 · Phase 4 67
First in 1990; this study’s year is marked. 74 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 108 across 1,843 interventional studies indexed under Substance-Related Disorders.
Median enrollment 104 across the 1,447 interventional studies, 234 across the 137 observational. Of the 1,174 that completed or were terminated, 376 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 1,589 have an industry lead sponsor. The 10 most frequent:
Clear Scientific, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Clear Scientific, Inc. has 1 study filed under Substance-Related Disorders — fewer than ten, so there is no comparison to draw.
99 of the studies in Substance-Related Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07566273Cornell UniversityMicropractices for Unhoused LGBTQ Youth | 2026-11 |
| NCT05897164Evidence-Based Practice Institute, Seattle, WAMobile Technology to Reduce Teen Substance Misuse | 2026-11-30 |
| NCT04317482University of ArkansasThe Human Stress Response in a Simulated ED Setting | 2026-12 |
| NCT05713695University of Massachusetts, WorcesterSupporting Treatment Access and Recovery Through Linkage and Support | 2026-12 |
| NCT03539575Yale UniversityCB1R in Synthetic Psychoactive Cannabinoids | 2026-12 |
Add all 99 to your calendar (.ics) → With an account.
Among the 1,589 studies in Substance-Related Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants.
Major Inclusion Criteria:
Major Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6 participants received a single dose of 2.7 mg/kg (2.5 mg/kg free acid) CS-1103 administered as solution for infusion by IV over 10 minutes. A diluted CS-1103 saline solution in an IV bag is used for drug administration.
Drug: CS-1103
6 participants received single dose of 8.0 mg/kg (7.5 mg/kg free acid) CS-1103 administered as solution for infusion by IV over 10 minutes. A diluted CS-1103 saline solution in an IV bag is used for drug administration.
Drug: CS-1103
6 participants received a single dose of 16.0 mg/kg (15.1 mg/kg free acid) CS-1103 administered as solution for infusion by IV over 10 minutes. A diluted CS-1103 saline solution in an IV bag is used for drug administration.
Drug: CS-1103
6 participants received a single dose of 19.0 mg/kg (17.9 mg/kg free acid) CS-1103 administered as solution for infusion by IV over 10 minutes. A diluted CS-1103 saline solution in an IV bag is used for drug administration.
Drug: CS-1103
2 participants for each cohort were administered with placebo. Total administered volume of saline matched administered volume for the corresponding CS-1103 solution in each cohort.
Drug: Sterile Saline
CS-1103 for infusion
Sterile Saline for Injection
Number of Participants With Treatment-Emergent Adverse Events (AEs)
Treatment-emergent adverse events assessed through physical examinations, vital signs (blood pressure, pulse rate, respiratory rate, oxygen saturation, and body temperature), electrocardiograms (digital 12-lead electrocardiograms (ECGs). Any correlation between CS-1103 plasma concentrations and changes in QT intervals will be noted), and laboratory parameters (clinical chemistry, hematology, coagulation, and urinalysis).
Time frame: 3 days plus 8 days for follow-up
Number of Participants by Severity of AEs
Severity of AEs was classified as mild, moderate, or severe (increasing severity). A subject experiencing multiple occurrences of an adverse event in a particular category was counted, at most, once for that category for each treatment.
Time frame: 3 days plus 8 days for follow-up
Plasma Pharmacokinetic (PK) Parameter: Cmax
Maximum concentration, obtained directly from the observed concentration versus time data.
Time frame: End-of-Infusion (EOI), 5, 10, 20, 30, 40 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 hr
Plasma PK Parameter: Tmax
Time of maximum observed blood plasma concentration (Cmax) of CS-1103
Time frame: End-of-Infusion (EOI), 5, 10, 20, 30, 40 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 hr
Plasma PK Parameter: t1/2
Terminal Elimination Half-life of CS-1103
Time frame: End-of-Infusion (EOI), 5, 10, 20, 30, 40 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 hr
Plasma PK Parameter: CL
Systemic Clearance of CS-1103
Time frame: End-of-Infusion (EOI), 5, 10, 20, 30, 40 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 hr
Plasma PK Parameter: Vz
Volume of Distribution of CS-1103
Time frame: End-of-Infusion (EOI), 5, 10, 20, 30, 40 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 hr
Urine PK Parameter: Fe (0-last)
Cumulative fraction of dose excreted in urine during the pooled collection intervals. Due to inherent error in measuring CS-1103 recovered in urine, the calculated recovery may exceed 100% of the dose.
Time frame: Time intervals from 0-24 hours after IV administration of CS-1103
| Milestone | Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) | Placebo |
|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 8 |
| Completed | 6 | 6 | 6 | 6 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Treatment-emergent adverse events assessed through physical examinations, vital signs (blood pressure, pulse rate, respiratory rate, oxygen saturation, and body temperature), electrocardiograms (digital 12-lead electrocardiograms (ECGs). Any correlation between CS-1103 plasma concentrations and changes in QT intervals will be noted), and laboratory parameters (clinical chemistry, hematology, coagulation, and urinalysis).
| Participants | Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) | Placebo |
|---|---|---|---|---|---|
| TEAEs | 1 | 1 | 2 | 4 | 0 |
| Related TEAEs | 0 | 0 | 1 | 4 | 0 |
| Serious TEAEs | 0 | 0 | 0 | 0 | 0 |
| TEAEs leading to study discontinuation | 0 | 0 | 0 | 0 | 0 |
| TEAEs leading to death | 0 | 0 | 0 | 0 | 0 |
Severity of AEs was classified as mild, moderate, or severe (increasing severity). A subject experiencing multiple occurrences of an adverse event in a particular category was counted, at most, once for that category for each treatment.
| Participants | Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) | Placebo |
|---|---|---|---|---|---|
| Mild | 1 | 1 | 2 | 4 | 0 |
| Moderate | 0 | 0 | 0 | 0 | 0 |
| Severe | 0 | 0 | 0 | 0 | 0 |
Maximum concentration, obtained directly from the observed concentration versus time data.
| μg/mL | Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) |
|---|---|---|---|---|
| Plasma Pharmacokinetic (PK) Parameter: Cmax | 20.78 ± 31.3 | 58.25 ± 17.7 | 156.9 ± 24.8 | 176.0 ± 17.9 |
Time of maximum observed blood plasma concentration (Cmax) of CS-1103
| hours | Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) |
|---|---|---|---|---|
| Plasma PK Parameter: Tmax | 0.235 (0.180 to 0.270) | 0.180 (0.180 to 0.330) | 0.180 (0.180 to 0.330) | 0.180 (0.180 to 0.250) |
Terminal Elimination Half-life of CS-1103
| hours | Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) |
|---|---|---|---|---|
| Plasma PK Parameter: t1/2 | 4.323 ± 26.4 | 4.118 ± 13.7 | 4.215 ± 17.4 | 4.558 ± 19.9 |
Systemic Clearance of CS-1103
| L/h | Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) |
|---|---|---|---|---|
| Plasma PK Parameter: CL | 0.04915 ± 24.2 | 0.04971 ± 16.1 | 0.04762 ± 20.6 | 0.05040 ± 17.3 |
Volume of Distribution of CS-1103
| L | Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) |
|---|---|---|---|---|
| Plasma PK Parameter: Vz | 0.3065 ± 15.0 | 0.2953 ± 7.8 | 0.2896 ± 12.0 | 0.3273 ± 24.0 |
Cumulative fraction of dose excreted in urine during the pooled collection intervals. Due to inherent error in measuring CS-1103 recovered in urine, the calculated recovery may exceed 100% of the dose.
| percentage of dose administered | Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) |
|---|---|---|---|---|
| Urine PK Parameter: Fe (0-last) | 91.58 ± 12.37 | 108.3 ± 4.227 | 101.0 ± 5.433 | 98.70 ± 9.129 |
Collected over 3 days plus 8 days for follow-up. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Placebo | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Event | Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) | Placebo |
|---|---|---|---|---|---|
| Eustachian tube dysfunctionEar and labyrinth disorders | 0/6 | 0/6 | 1/6 | 2/6 | 0/8 |
| SneezingRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 2/6 | 0/8 |
| PalpitationsCardiac disorders | 1/6 | 0/6 | 0/6 | 0/6 | 0/8 |
| TachycardiaCardiac disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/8 |
| TinnitusEar and labyrinth disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/8 |
| Periorbital oedemaEye disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/8 |
| Abdominal painGastrointestinal disorders | 1/6 | 0/6 | 0/6 | 0/6 | 0/8 |
| Gingival painGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/8 |
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/8 |
| Skin abrasionInjury, poisoning and procedural complications | 1/6 | 0/6 | 0/6 | 0/6 | 0/8 |
| Age, Continuous(years) | Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 29.7 ± 10.7 | 30.3 ± 8.3 | 39.5 ± 9.0 | 38.5 ± 7.9 | 36.3 ± 10.4 | 34.9 ± 9.7 |
| Sex: Female, Male(Participants) | Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 1 | 3 | 0 | 0 | 4 |
| Male | 6 | 5 | 3 | 6 | 8 | 28 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 0 | 2 | 0 | 4 |
| Not Hispanic or Latino | 6 | 4 | 6 | 4 | 8 | 28 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 4 | 5 | 2 | 6 | 18 |
| White | 4 | 2 | 1 | 4 | 2 | 13 |
| More than one race | 1 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| BMI(kg/m^2) | Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 25.815 ± 2.479 | 24.728 ± 3.451 | 24.528 ± 2.731 | 25.975 ± 2.602 | 26.161 ± 2.308 | 25.487 ± 2.624 |
| Weight(kg) | Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 83.30 ± 11.81 | 72.97 ± 8.30 | 68.32 ± 6.93 | 76.20 ± 9.27 | 79.44 ± 6.77 | 76.26 ± 9.60 |
| Height(cm) | Cohort 1 (2.5 mg/kg CS-1103 [Free Acid]) | Cohort 2 (7.5 mg/kg CS-1103 [Free Acid]) | Cohort 3 (15.1 mg/kg CS-1103 [Free Acid]) | Cohort 4 (17.9 mg/kg CS-1103 [Free Acid]) | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 179.23 ± 6.59 | 170.80 ± 10.11 | 166.97 ± 6.65 | 171.12 ± 5.98 | 174.63 ± 5.42 | 172.68 ± 7.73 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2024 to primary completion in May 2024, 3 months.
Results were first posted in Nov 2025, 1 year 5 months after primary completion.
Of 24 industry-sponsored phase 1 interventional studies under Substance-Related Disorders, half reached primary completion within 4 months of starting (the median); a quarter within 3 and three quarters within 9. This study's 3 months is below that.
Counting every sponsor, half of 54 studies reached it within 12 months; a quarter within 4 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CS-1103
Clear Scientific, Inc.